Biomarkers of cell death applicable to early clinical trials

Experimental Cell Research

Volumn 318, Issue 11, 2012, Pages 1252-1259

  Dean, Emma ^a   Greystoke, Alastair ^a   Ranson, Malcolm ^a   Dive, Caroline ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Apoptosis; Biomarkers; Cell death; Circulating; Predictive

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 18;

APOPTOSIS; BLOOD SAMPLING; CELL DEATH; HUMAN; MOLECULAR IMAGING; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTIVE VALIDITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR BIOPSY; VALIDATION STUDY;

EID: 84861669052     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.03.020     Document Type: Review

References (64)

1. Biomarkers Definitions Working Group National Institute of Health Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69:89-95.
2. Goulart B.H., Clark J.W., Pien H.H., Roberts T.G., Finkelstein S.N., Chabner B.A. Trends in the use and role of biomarkers in phase I oncology trials. Clin. Cancer Res. 2007, 13:6719-6726.
3. Yap T.A., Sandhu S.K., Workman P., de Bono J.S. Envisioning the future of early anticancer drug development. Nat. Rev. Cancer 2010, 10:514-523.
4. Duffy M.J. Predictive markers in breast and other cancers: a review. Clin. Chem. 2005, 51:494-503.
5. Kane R.C., Farrell A.T., Sridhara R., Pazdur R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin. Cancer Res. 2006, 12:2955-2960.
6. Glassman R.H., Ratain M.J. Biomarkers in early cancer drug development: limited utility. Clin. Pharmacol. Ther. 2009, 85:134-135.
7. Carden C.P., Banerji U., Kaye S.B., Workman P., de Bono J.S. From darkness to light with biomarkers in early clinical trials of cancer drugs. Clin. Pharmacol. Ther. 2009, 85:131-133.
8. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
9. Evan G.I., Wyllie A.H., Gilbert C.S., Littlewood T.D., Land H., Brooks M., Waters C.M., Penn L.Z., Hancock D.C. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992, 69:119-128.
10. Letai A.G. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat. Rev. Cancer 2008, 8:121-132.
11. Parton M., Krajewski S., Smith I., Krajewska M., Archer C., Naito M., Ahern R., Reed J., Dowsett M. Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy. Clin. Cancer Res. 2002, 8:2100-2108.
12. Kaufmann S.H., Earnshaw W.C. Induction of apoptosis by cancer chemotherapy. Exp. Cell Res. 2000, 256:42-49.
13. Weinstein I.B., Joe A.K. Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol. 2006, 3:448-457.
14. Rehman F.L., Lord C.J., Ashworth A. Synthetic lethal approaches to breast cancer therapy. Nat. Rev. Clin. Oncol. 2010, 7:718-724.
15. Ward T.H., Cummings J., Dean E., Greystoke A., Hou J.M., Backen A., Ranson M., Dive C. Biomarkers of apoptosis. Br. J. Cancer 2008, 99:841-846.
16. Dean E.J., Cummings J., Roulston A., Berger M., Ranson M., Blackhall F., Dive C. Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer. Neoplasia 2011, 13:339-347.
17. Dive C., Hickman J.A. Drug-target interactions: only the first step in the commitment to a programmed cell death?. Br. J. Cancer 1991, 64:192-196.
18. Kaufmann S.H., Vaux D.L. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003, 22:7414-7430.
19. Leber B., Geng F., Kale J., Andrews D.W. Drugs targeting bcl-2 family members as an emerging strategy in cancer. Expert Rev. Mol. Med. 2010, 12:e28.
20. Cummings J., Ward T.H., Greystoke A., Ranson M., Dive C. Biomarker method validation in anticancer drug development. Br. J. Pharmacol. 2008, 153:646-656.
21. Wyllie A.H., Kerr J.F., Currie A.R. Cellular events in the adrenal cortex following ACTH deprivation. J. Pathol. 1972, 106. Pix.
22. Kroemer G., Galluzzi L., Vandenabeele P., Abrams J., Alnemri E.S., Baehrecke E.H., Blagosklonny M.V., El-Deiry W.S., Golstein P., Green D.R., Hengartner M., Knight R.A., Kumar S., Lipton S.A., Malorni W., Nunez G., Peter M.E., Tschopp J., Yuan J., Piacentini M., Zhivotovsky B., Melino G. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009, 16:3-11. Nomenclature Committee on Cell Death 2009.
23. Guarneri V., Frassoldati A., Ficarra G., Puglisi F., Andreetta C., Michelotti A., Cresti N., Boni C., Bisagni G., Berardi R., Battelli N., Santoro A., Banna G., Bottini A., Di Blasio B., Maiorana A., Piacentini F., Giovannelli S., Jovic G., Conte P. Phase II, randomized trial of preoperative epirubicin-paclitaxel±gefitinib with biomarker evaluation in operable breast cancer. Breast Cancer Res. Treat. 2008, 110:127-134.
24. Wang L.S., Arnold M., Huang Y.W., Sardo C., Seguin C., Martin E., Huang T.H., Riedl K., Schwartz S., Frankel W., Pearl D., Xu Y., Winston J., Yang G.Y., Stoner G. Modulation of genetic and epigenetic biomarkers of colorectal cancer in humans by black raspberries: a phase I pilot study. Clin. Cancer Res. 2011, 17:598-610.
25. Tong W.G., Chen R., Plunkett W., Siegel D., Sinha R., Harvey R.D., Badros A.Z., Popplewell L., Coutre S., Fox J.A., Mahadocon K., Chen T., Kegley P., Hoch U., Wierda W.G. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J. Clin. Oncol. 2010, 28:3015-3022.
26. Carter B.Z., Mak D.H., Morris S.J., Borthakur G., Estey E., Byrd A.L., Konopleva M., Kantarjian H., Andreeff M. XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis 2011, 16:67-74.
27. Klimek V.M., Fircanis S., Maslak P., Guernah I., Baum M., Wu N., Panageas K., Wright J.J., Pandolfi P.P., Nimer S.D. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin. Cancer Res. 2008, 14:826-832.
28. Symmans W.F., Volm M.D., Shapiro R.L., Perkins A.B., Kim A.Y., Demaria S., Yee H.T., McMullen H., Oratz R., Klein P., Formenti S.C., Muggia F. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin. Cancer Res. 2000, 6:4610-4617.
29. Cummings J., Hodgkinson C., Odedra R., Sini P., Heaton S.P., Mundt K.E., Ward T.H., Wilkinson R.W., Growcott J., Hughes A., Dive C. Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity. Mol. Cancer Ther. 2008, 7:455-463.
30. Micha D., Cummings J., Shoemaker A., Elmore S., Foster K., Greaves M., Ward T., Rosenberg S., Dive C., Simpson K. Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer. Clin. Cancer Res. 2008, 14:7304-7310.
31. Barr P.M., Lazarus H.M., Cooper B.W., Schluchter M.D., Panneerselvam A., Jacobberger J.W., Hsu J.W., Janakiraman N., Simic A., Dowlati A., Remick S.C. Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant. Am. J. Hematol. 2009, 84:484-487.
32. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., Debatin K.M., Krammer P.H., Peter M.E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998, 17:1675-1687.
33. Cummings J., Ranson M., Lacasse E., Ganganagari J.R., St-Jean M., Jayson G., Durkin J., Dive C. Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br. J. Cancer 2006, 95:42-48.
34. Cummings J., Ward T.H., LaCasse E., Lefebvre C., St-Jean M., Durkin J., Ranson M., Dive C. Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br. J. Cancer 2005, 92:532-538.
35. Holdenrieder S., Stieber P., Bodenmuller H., Fertig G., Furst H., Schmeller N., Untch M., Seidel D. Nucleosomes in serum as a marker for cell death. Clin. Chem. Lab. Med. 2001, 39:596-605.
36. Holdenrieder S., Nagel D., Schalhorn A., Heinemann V., Wilkowski R., von Pawel J., Raith H., Feldmann K., Kremer A.E., Muller S., Geiger S., Hamann G.F., Seidel D., Stieber P. Clinical relevance of circulating nucleosomes in cancer. Ann. N. Y. Acad. Sci. 2008, 1137:180-189.
37. Gibb A., Ranson M., Greystoke A., Linton K., Neeson S., Illidge T., Smith E., Dive C., Pettit A., Lister A., Johnson P., Radford J. A phase I study to investigate dose escalation of doxorubicin in cycles 1-3 of ABVD chemotherapy for Hodgkin lymphoma and to correlate this with blood-borne biomarkers of tumour response and toxicity. 11th International Conference on Malignant Lymphoma 2011.
38. O'Brien S.M., Claxton D.F., Crump M., Faderl S., Kipps T., Keating M.J., Viallet J., Cheson B.D. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009, 113:299-305.
39. Greystoke A., Cummings J., Ward T., Simpson K., Renehan A., Butt F., Moore D., Gietema J., Blackhall F., Ranson M., Hughes A., Dive C. Optimisation of circulating biomarkers of cell death for routine clinical use. Ann. Oncol. 2008, 19:990-995.
40. de Haas E.C., di Pietro A., Simpson K.L., Meijer C., Suurmeijer A.J., Lancashire L.J., Cummings J., de Jong S., de Vries E.G., Dive C., Gietema J.A. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia 2008, 10:1041-1048.
41. Olofsson M.H., Ueno T., Pan Y., Xu R., Cai F., van der Kuip H., Muerdter T.E., Sonnenberg M., Aulitzky W.E., Schwarz S., Andersson E., Shoshan M.C., Havelka A.M., Toi M., Linder S. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin. Cancer Res. 2007, 13:3198-3206.
42. Dive C., Smith R.A., Garner E., Ward T., George-Smith S.S., Campbell F., Greenhalf W., Ghaneh P., Neoptolemos J.P. Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer. Br. J. Cancer 2010, 102:577-582.
43. Hou J.M., Greystoke A., Lancashire L., Cummings J., Ward T., Board R., Amir E., Hughes S., Krebs M., Hughes A., Ranson M., Lorigan P., Dive C., Blackhall F.H. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am. J. Pathol. 2009, 175:808-816.
44. Dean E., Jodrell D., Connolly K., Danson S., Jolivet J., Durkin J., Morris S., Jowle D., Ward T., Cummings J., Dickinson G., Aarons L., Lacasse E., Robson L., Dive C., Ranson M. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. J. Clin. Oncol. 2009, 27:1660-1666.
45. Greystoke A., O'Connor J.P.B., Linton K., Taylor M.B., Cummings J., Ward T., Hughes A., Maders F., Ranson M., Radford J.A., Dive C. Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. Br. J. Cancer 2011, 104:719-725.
46. Steele N.L., Plumb J.A., Vidal L., Tjornelund J., Knoblauch P., Rasmussen A., Ooi C.E., Buhl-Jensen P., Brown R., Evans T.R., DeBono J.S. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin. Cancer Res. 2008, 14:804-810.
47. Esaki T., Seto T., Ariyama H., Arita S., Fujimoto C., Tsukasa K., Kometani T., Nosaki K., Hirai F., Yagawa K. Phase I study to assess the safety, tolerability and pharmacokinetics of AZD4877 in Japanese patients with solid tumors. Arch. Drug Inf. 2011, 4:23-31.
48. Sarker D., Workman P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv. Cancer Res. 2007, 96:213-268.
49. Arkenau H.T., Plummer R., Molife L.R., Olmos D., Yap T.A., Squires M., Lewis S., Lock V., Yule M., Lyons J., Calvert H., Judson I. A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Ann. Oncol. 2011, 10.1093/annonc/mdr451.
50. Curry J., Angove H., Fazal L., Lyons J., Reule M., Thompson N., Wallis N. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283. Cell Cycle 2009, 8:1921-1929.
51. Gandhi L., Camidge D.R., Ribeiro de Oliveira M., Bonomi P., Gandara D., Khaira D., Hann C.L., McKeegan E.M., Litvinovich E., Hemken P.M., Dive C., Enschede S.H., Nolan C., Chiu Y.L., Busman T., Xiong H., Krivoshik A.P., Humerickhouse R., Shapiro G.I., Rudin C.M. Phase I study of navitoclax (ABT-263), a novel bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J. Clin. Oncol. 2011, 29:909-916.
52. Hwang J.J., Kuruvilla J., Mendelson D., Pishvaian M.J., Deeken J.F., Siu L.L., Berger M.S., Viallet J., Marshall J.L. Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin. Cancer Res. 2010, 16:4038-4045.
53. Pan Y., Xu R., Peach M., Huang C.P., Branstetter D., Novotny W., Herbst R.S., Eckhardt S.G., Holland P.M. Evaluation of pharmacodynamic biomarkers in a phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours. Br. J. Cancer 2011, 105:1830-1838.
54. Soria J.C., Márk Z., Zatloukal P., Szima B., Albert I., Juhász E., Pujol J.L., Kozielski J., Baker N., Smethurst D., Hei Y.J., Ashkenazi A., Stern H., Amler L., Pan Y., Blackhall F. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J. Clin. Oncol. 2011, 29:4442-4451.
55. Alunni-Fabbroni M., Sandri M.T. Circulating tumour cells in clinical practice: methods of detection and possible characterization. Methods 2010, 50:289-297.
56. Miller M.C., Doyle G.V., Terstappen L.W. Significance of circulating tumor cells detected by the Cell Search system in patients with metastatic breast colorectal and prostate cancer. J. Oncol. 2010, 2010:617421.
57. Krebs M.G., Sloane R., Priest L., Lancashire L., Hou J.M., Greystoke A., Ward T.H., Ferraldeschi R., Hughes A., Clack G., Ranson M., Dive C., Blackhall F.H. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J. Clin. Oncol. 2011, 29:1556-1563.
58. Larson C.J., Moreno J.G., Pienta K.J., Gross S., Repollet M., O'hara S.M., Russell T., Terstappen L.W. Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry A 2004, 62:46-53.
59. Mehes G., Witt A., Kubista E., Ambros P.F. Circulating breast cancer cells are frequently apoptotic. Am. J. Pathol. 2001, 159:17-20.
60. Hauck P., Chao B.H., Litz J., Krystal G.W. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Mol. Cancer Ther. 2009, 8:883-892.
61. Belhocine T.Z., Blankenberg F.G. 99mTc-annexin A5 uptake and imaging to monitor chemosensitivity. Methods Mol. Med. 2005, 111:363-380.
62. Blankenberg F.G. Monitoring of treatment-induced apoptosis in oncology with PET and SPECT. Curr. Pharm. Des. 2008, 14:2974-2982.
63. Zhou D., Chu W., Chen D.L., Wang Q., Reichert D.E., Rothfuss J., D'Avignon A., Welch M.J., Mach R.H. [18F]- and [11C]-labeled N-benzyl-isatin sulfonamide analogues as PET tracers for apoptosis: synthesis, radiolabeling mechanism, and in vivo imaging study of apoptosis in fas-treated mice using [11C]WC-98. Org. Biomol. Chem. 2009, 7:1337-1348.
64. Chen K., Chen X. Positron emission tomography imaging of cancer biology: current status and future prospects. Semin. Oncol. 2011, 38:70-86.